Brief: Elevai Biosciences highlights Past Positive Preclinical Data Showing Potential Of El-32, A Dual Myostatin & Activin-A Blocker, For The Treatment Of Obesity

PMGC Holdings

21/10/2024 13:16

Oct 21 (Reuters) - Elevai Labs Inc  ELAB.O :
    * ELEVAI BIOSCIENCES, A SUBSIDIARY OF ELEVAI LABS INC.,
HIGHLIGHTS
PAST POSITIVE PRECLINICAL DATA SHOWING POTENTIAL OF EL-32, A
DUAL MYOSTATIN & ACTIVIN-A BLOCKER, FOR THE TREATMENT OF OBESITY
    * ELEVAI: EL-32 PRECLINICAL RESULTS SHOWED STATISTICALLY
SIGNIFICANT INCREASES IN GRIP STRENGTH, MOTOR FUNCTION & BODY
COMPOSITION IN AGED MOUSE MODEL
    * ELEVAI: TO CONDUCT ADDITIONAL ANIMAL STUDIES TO ADVANCE
EL-32
TOWARDS IND APPLICATION

Source text for Eikon:  ID:nGNX5gcf1H 
Further company coverage:  ELAB.O 

 ((Reuters.Briefs@thomsonreuters.com))